View Older Stories View More Recent Stories

Dec 14, 2021 07:00AM PharmaTher Announces Positive Research Results for LSD Microneedle Patch
Nov 30, 2021 07:00AM PharmaTher Granted New Japanese Patent for KETABET™ (Ketamine Combination Formulation), Strengthening Global Patent Portfolio
Nov 24, 2021 07:30AM PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus
Nov 11, 2021 07:59AM PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch
Nov 3, 2021 07:30AM PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch
Nov 3, 2021 07:00AM Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of Psilocybin Microneedle Patch
Nov 1, 2021 09:30AM PharmaTher Provides Research Update on Microneedle Patch Delivery Technologies for Psychedelics
Oct 27, 2021 05:34PM PharmaTher Provides Business Update and Releases Financial Results for the First Quarter of Fiscal 2022
Oct 27, 2021 08:49AM World Leading Drug Delivery Researcher Professor Ryan Donnelly Joins PharmaTher as Scientific and Technical Advisor
Oct 19, 2021 07:00AM PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products
Oct 13, 2021 07:00AM PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome
Oct 6, 2021 09:03AM PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease
Sep 29, 2021 11:20AM PharmaTher Retains Former FDA Psychiatry Division Director Dr. Thomas Laughren as Regulatory Affairs Advisor
Sep 28, 2021 05:41PM PharmaTher Announces Closing of CAD$10 Million Private Placement with Institutional Investors
Sep 21, 2021 09:00AM PharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded Fund
Sep 13, 2021 07:00AM PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022
Sep 9, 2021 08:51AM PharmaTher to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Sep 7, 2021 05:37PM PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year Ended May 31, 2021
Aug 4, 2021 08:00AM PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral Sclerosis
Jul 21, 2021 08:00AM PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation
Jun 28, 2021 08:00AM PharmaTher To Participate in Grizzle Psychedelics Con
Jun 16, 2021 08:00AM PharmaTher To Present At The H.C. Wainwright Psychedelics In Psychiatry And Beyond Virtual Conference
Jun 15, 2021 08:00AM PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression
Jun 10, 2021 08:00AM PharmaTher Provides Research and Development Update and Milestones for 2021
Jun 1, 2021 08:00AM PharmaTher and TSRL Enter into Co-Development Agreement For Microneedle Patch Delivery Technology for Psychedelics and Antivirals
May 27, 2021 08:00AM PharmaTher Collaborates with MediSynergics to Develop Patented Ketamine Formulation for Pain Disorders and to Discover Novel Psychedelic Formulations
May 25, 2021 08:05AM PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig’s Disease
May 20, 2021 09:28AM Accomplished Clinical Researcher Matthew Macaluso Joins as Scientific and Clinical Advisor for PharmaTher’s Ketamine Programs
May 17, 2021 07:59AM PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson’s Disease
Apr 27, 2021 07:00AM PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics with panaceAI™
Apr 20, 2021 07:00AM PharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical Trial Evaluating Ketamine in the Treatment of Parkinson’s Disease
Apr 15, 2021 09:00AM PharmaTher Provides Update on Psychedelic Product Programs
Apr 13, 2021 11:28AM Newscope Announces Name Change to PharmaTher Holdings Ltd.
Apr 8, 2021 10:40AM Newscope Announces Name Change
Apr 1, 2021 02:01PM Newscope Capital Provides Dial-In Information for Special Meeting
Mar 24, 2021 07:00AM PharmaTher Advancing Research for Novel Microneedle Delivery of Ketamine
Mar 16, 2021 09:15AM World Leading Depression Researcher Dr. Maurizio Fava Joins PharmaTher as Scientific and Clinical Advisor
Mar 2, 2021 07:00AM PharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou Gehrig’s Disease
Mar 1, 2021 07:57AM Newscope Announces DTC Eligibility of Its Common Shares in the United States
Feb 23, 2021 07:00AM PharmaTher Announces Research Collaboration with Terasaki Institute for Novel Microneedle Delivery of Psychedelic Pharmaceuticals
Feb 17, 2021 09:01AM PharmaTher Announces Sale of Psilocybin Program
Feb 4, 2021 08:00AM PharmaTher Announces Successful Completion of Pre-IND Meeting with FDA for the Clinical Development of Ketamine in the Treatment of Parkinson’s Disease
Feb 1, 2021 07:59AM PharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Deliver Ketamine
Jan 19, 2021 07:33AM PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation Targeting Mental Health, Neurological and Pain Disorders
Jan 13, 2021 08:30AM PharmaTher Approved to Trade on the OTCQB Venture Market
Dec 30, 2020 08:00AM PharmaTher Announces Application for OTCQB Listing
Dec 21, 2020 07:59AM PharmaTher Signs LOI to Sell Psilocybin Program to Revive Therapeutics
Dec 21, 2020 07:59AM Revive Therapeutics Announces LOI to Acquire PharmaTher’s Psilocybin Program
Dec 15, 2020 07:00AM PharmaTher Files U.S. Patent for Novel Combinations of Psilocybin and FDA Approved Drugs to Treat Neurological Disorders
Dec 10, 2020 07:00AM PharmaTher Granted Pre-IND Meeting with the FDA for Ketamine in Parkinson’s Disease
View More Recent Stories View Older Stories